VistaGen Therapeutics News

Vistagen Therapeutics Analyst Ratings

BenzingaDec 7, 2023 05:33 ET

Hearing Vistagen Therapeutics Upgraded From A Hold To A Buy At Jefferies; Price Target $15

BenzingaDec 6, 2023 19:10 ET

Vistagen Therapeutics Analyst Ratings

BenzingaNov 14, 2023 12:46 ET

VistaGen Therapeutics' Robust Financial Position and Promising Pipeline Underpin Buy Rating: A Comprehensive Analysis

TipRanksNov 11, 2023 10:15 ET

Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Rhythm Pharmaceuticals (RYTM)

TipRanksOct 18, 2023 13:40 ET

Maxim Cuts Price Target on VistaGen Therapeutics to $12 From $30, Maintains Buy Rating

MT NewswiresOct 17, 2023 13:43 ET

Maxim Group Upgrades Vistagen Therapeutics to Buy, Announces $30 Price Target

BenzingaAug 7, 2023 19:09 ET

Vistagen Therapeutics Analyst Ratings

BenzingaAug 7, 2023 19:04 ET

Analysts Offer Insights on Healthcare Companies: VistaGen Therapeutics (VTGN) and Humacyte (HUMA)

TipRanksMar 24, 2023 10:41 ET

Maxim Group Sticks to Their Hold Rating for VistaGen Therapeutics (VTGN)

TipRanksFeb 9, 2023 10:16 ET

Maxim Group Sticks to Its Hold Rating for VistaGen Therapeutics (VTGN)

TipRanksDec 7, 2022 13:05 ET

Robert W. Baird Reaffirms Their Hold Rating on VistaGen Therapeutics (VTGN)

TipRanksNov 13, 2022 22:50 ET

Maxim Group Remains a Hold on VistaGen Therapeutics (VTGN)

TipRanksAug 13, 2022 07:35 ET

VistaGen Therapeutics Cut to Hold From Buy by Maxim Group

Dow JonesJul 26, 2022 09:10 ET

VistaGen Therapeutics analyst ratings

Benzinga Analyst RatingsJul 26, 2022 09:00 ET

Vistagen downgraded to neutral at Baird on pivotal trial failure

Seeking AlphaJul 25, 2022 10:05 ET

VistaGen Therapeutics Cut to Market Perform From Outperform by William Blair

Dow JonesJul 22, 2022 10:02 ET

VistaGen Therapeutics analyst ratings

Benzinga Analyst RatingsJul 22, 2022 09:54 ET